EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability

Shenghua Gao, Letian Song, Katharina Sylvester, Beatrice Mercorelli iD, Arianna Loregian iD, Karoly Toth, Renato H Weiße iD, Abibe Useini iD, Norbert Sträter iD, Mianling Yang, Bing Ye, Ann E Tollefson und 3 weitere

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c01876 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Shenghua Gao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Shandong University,…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: European Commission, Associazione Italiana per la Ricerca sul Cancro, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ongoing transmission of SARS-CoV-2 necessitates the development of additional potent antiviral agents capable of combating the current highly infectious variants and future coronaviruses. Here, we present the discovery of potent nonpeptide main protease (Mpro) inhibitors with prominent antiviral activity and improved pharmacokinetic properties. Three series of 1,2,4-trisubstituted piperazine derivatives were designed and synthesized, and the optimal GC-78-HCl demonstrated high enzyme-inhibitory potency (IC50 = 0.19 μM) and exhibited excellent antiviral activity (EC50 = 0.40 μM), reaching the same level as Nirmatrelvir (EC50 = 0.38 μM). Additionally, GC-78-HCl displayed potent antiviral activities against various SARS-CoV-2 variants as well as HCoV-OC43 and HCoV-229E, indicating its potential broad-spectrum anticoronaviral activity. Notably, the pharmacokinetic properties of GC-78-HCl were somewhat enhanced compared to those of the lead compound. Furthermore, the cocrystal and molecular docking elucidated the mechanism of action. In conclusion, we discovered a novel nonpeptidic Mpro inhibitor with promising antiviral activity and a favorable pharmacokinetic profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansMolecular Docking SimulationProtease InhibitorsAntiviral AgentsPiperazines

Substanzen

Protease InhibitorsAntiviral AgentsPiperazines

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Shandong University, Ji'nan 250012, China.
  • Shenzhen Research Institute of Shandong University, A301 Virtual University Park in South District of Shenzhen, Shenzhen, Guangdong 518057, PR China.
  • PharmaCenter Bonn & Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53113 Bonn, Germany.
  • Department of Molecular Medicine, University of Padua, Via Gabelli 63, 35121 Padua, Italy.
  • Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri 63103, United States.
  • Institute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, Leipzig 04103, Germany.

ORCID-Profile: Beatrice Mercorelli, Arianna Loregian, Renato H Weiße, Abibe Useini, Norbert Sträter, Christa E Müller, Xinyong Liu, Peng Zhan

Förderung

  • European Commission
  • Associazione Italiana per la Ricerca sul Cancro
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Ministero dell'Universit? e della Ricerca
  • Fondazione Cassa di Risparmio di Padova e Rovigo
  • Natural Science Foundation of Shandong Province
  • Science Fund for Distinguished Young Scholars of Shandong Province
  • Universit? degli Studi di Padova

Zitieren

APA

Gao, S., Song, L., Sylvester, K., Mercorelli, B., Loregian, A., Toth, K., Weiße, R. H., Useini, A., Sträter, N., Yang, M., Ye, B., Tollefson, A. E., Müller, C. E., Liu, X., & Zhan, P. (2023). Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01876

Vancouver

Gao S, Song L, Sylvester K, Mercorelli B, Loregian A, Toth K, et al. Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01876

BibTeX
@article{Gao2023,
  author = {Gao, Shenghua and Song, Letian and Sylvester, Katharina and Mercorelli, Beatrice and Loregian, Arianna and Toth, Karoly and Weiße, Renato H and Useini, Abibe and Sträter, Norbert and Yang, Mianling and Ye, Bing and Tollefson, Ann E and Müller, Christa E and Liu, Xinyong and Zhan, Peng},
  title = {Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c01876}
}
Kostenlos starten →